The application of nanobody in CAR-T therapy. Biomolecules. 2021;11(2):238. 82. Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24. 83. Liu G, Rui W, Zhao X, Lin X. Enhancing...
The discovery of nanobodies (Nbs) originated from a class of antibodies (Abs) found in dromedary camels, known as heavy-chain-only antibodies (HCAbs), which lack light chains and CH1 domains. Similar HCAbs have also been identified in cartilaginous fish [1]. This single-domain structure, la...
HSP70) suggest the potential application of CAR technology for targeted immunotherapies in asthma. CAR technology offers an approach to engineer immune cells for antigen-specific recognition [17]. Several researchers have explored the potential of CAR-T cell therapy for allergic ...
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, that specifically targets antigens expressed on the surface...
CAR-T cells and their uses in fundamental research and clinical trials are examined after a description of tumor antigens in breast cancer as well as their therapeutic relevance. We hope that this review will provide a useful update on the application of CAR-T cells in the treatment of ...
Nanobodies (Nbs), miniature antibodies consisting solely of the variable region of heavy chains, exhibit unique properties such as small size, high stability, and strong specificity, making them highly promising for disease diagnosis and treatment. The engineering production of Nbs has evolved into a...
For each nanobody family, we subcloned the member that had shown the highest staining intensity of CD38-transfected cells in the periplasmic screening assay (FigureS2b). To circumvent the problem of endotoxin contamination of nanobodies inherent to theE. coliexpression system, we recloned the nano...
etc. The production scale is small, and its application in the clinic is not satisfactory [1]. CAR-T cell therapy involves genetically engineering T cells to express antigen-specific, non-MHC-restricted receptors that could target and attack specific pathological cells to exert a therapeutic effect...
Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity through the recognition of particular antigens, has emerged as one of the most rapidly advancing modalities in immunotherapy, demonstrating substantial success aga
Despite substantial advances in improving patient outcomes, chimeric antigen receptor (CAR)-T-cell therapy still faces the challenge of relapse. A considerable portion of these cases involve the loss of the target antigen1. Although various bispecific CAR-T-cell strategies, such as CD19/CD20 or ...